Sterling Pharma Solutions
Cramlington, United Kingdom
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Sterling Pharma Solutions
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Cramlington, United Kingdom
- Modalities
- ADC, Bioconjugation, HPAPI/Small Molecule API, Peptides, Linker-Payload Synthesis
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Sterling Pharma Solutions
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesADC, Bioconjugation, HPAPI/Small Molecule API, Peptides, Linker-Payload Synthesis
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (5 modalities)
Recent News 10 articles
CDMO Sterling burnishes its U.S. credentials with buyout of North Carolina facility - Fierce Pharma
Novartis sells pair of manufacturing plants as Sandoz strategic review rolls on - Fierce Pharma
Sterling Pharma Solutions expands early phase development - Manufacturing Chemist
CDMO Sterling Pharma Solutions created from MBO of U.K. facility - Fierce Pharma
GHO Capital and Partners Group invest in Sterling Pharma - GlobeNewswire
The CDMO/CMO Report: High-Potency API Manufacturing - DCAT Value Chain Insights
ADC handling: the whole story of a facility startup - Cleanroom Technology
CDMO Sterling Pharma continues buying spree with former Alcami ingredients plant pickup - Fierce Pharma
Sterling Pharma Solutions to Invest $3 Million in Germantown, WI Plant - Pharmaceutical Commerce
Cabaletta corrals cell therapy Legend—Chutes & Ladders - Fierce Biotech
Frequently Asked Questions About Sterling Pharma Solutions
What is Sterling Pharma Solutions's CDMO Signal Score?
Sterling Pharma Solutions has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Sterling Pharma Solutions for a manufacturing program?
Use the free AI matchmaker to compare Sterling Pharma Solutions against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Abzena
Raleigh, NC
ADC, AOC, RDC, Biologics, mAb, HPAPI, Bioconjugation
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV, ADC
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 83.6
Biologics, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC